Grégoire Franoux

An important step in Samabriva's development, providing our international partners with industrial capacity

22

3 Comments

  🚀 BioPark Charleroi Drives Growth in the European Biotechnology Sector 🧬   Last July, Brussels South Charleroi BioPark took a significant step toward establishing itself as a global player in biomanufacturing. This ambitious project aims to transform its campus, tripling its size and workforce to reach 10,000 jobs in the coming years. Backed by the UMONS and key partners, the plan focuses on strengthening the local life sciences ecosystem through cutting-edge infrastructure and innovation initiatives, including the EU Biotech Campus. These efforts will foster a vibrant environment for startups and established companies alike, promoting research and development in biotechnology, pharmaceuticals, and biomedical research.   For ACCIÓ Brussels , this expansion exemplifies collaboration and development in the biotech sector. Catalonia leads Spain's biotechnology landscape, hosting nearly 25% of all companies in the field. ACCIÓ supports Catalan firms in building networks, attracting investments, and enhancing innovation, with the aim of replicating successful initiatives like BioPark. By fostering connections and partnerships, this development opens doors for synergies and opportunities between Wallonia and Catalonia, ultimately enhancing the competitiveness of both regions in the global biotechnology market. 🌍🔬   #InvestCatalonia #Biotech #Startups #Biopark

14

1 Comment

Great news for miDiagnostics, who secured a €30 Million Series D funding round to advance an innovative sterility test and other quality control tests for use in the biopharma industry! The funding round is led by Thermo Fisher Scientific and strengthened by Alychlo, VMF Invest and Pamica. Katleen Verleysen, CEO at miDiagnostics, says: "We advance our mission to revolutionize sterility testing in the biopharma sector. This funding will enable us to expedite our development efforts and leverage Thermo Fisher’s expertise for the commercialization of our pioneering products.” Exciting times for this imec spin-off! Congratulations!

102

3 Comments

Manufacturing costs of medicinal products, especially new and highly innovative therapies, is currently one of the most discussed topics in the field. SwiftPharma, a Belgian biotech startup using plants to produce life-saving proteins at low costs, collaborates with Medace to improve the quality and scalability of their production. SwiftPharma makes, among other things, a virus inhibitor for preventing HIV infection and a biosimilar for lowering the costs of oncology treatments. Their technology is market disruptive and represents a paradigm shift in sustainable bioproduction. Read this article to discover how SwiftPharma creates impact and rewrites the possibilities in healthcare with their plant-based solutions 👇🏼 #cleanroom #plantbased #biotech #innovation #healthcare 

15

⭐ Right place, right people, right time, and a wonderful partnership is born ! So grateful to BVI.EU, invest.bw and Université catholique de Louvain for the eagerness to come together in this TechBio venture, gathering science, venture capital, real estate and entrepreneurship.⭐ An AI-driven drug discovery venture builder is born under brand name Quantum BioVenture Studio to foster AI-first biology research approaches in drug discovery. Getting closer to taking humans as a model for humans is therapeutic target identification, the studio will act as a start-up factory leveraging the most advanced machine learning innovations on human multiomics big data. With a focus on rare diseases, and more common diseases related to them through gene regulatory networks, QBVS will work hand in hand with Louvain4Rare coordinated by Prof Olivier Devuyst and TRAIL - TRusted AI Labs co-founded by Prof Benoit Macq. Last but not least, Quantum BioVenture Studio is the first tenant, and at the same time the growth engine, of its mother initiative Quantum Biospace. 🚀 Discover the article release issued this morning in L'Echo. Thanks Olivier Gosset for the sound coverage. Michel Meers | Geoffroy Dumonceau de Bergendal | Pierre de Waha | Xavier Bocquet | Xavier Bastin | Alexia Autenne #techbio #venturestudio #drugdiscovery #ai https://lnkd.in/e68Y-q_S

8

🔬 CDMO News Highlights You Might Have Missed Last Week: 1️⃣SAMABRIVA launches a state-of-the-art, multi-million-euro biomanufacturing facility in Belgium. 2️⃣ Matica Biotechnology, Inc. secures a pivotal GMP manufacturing deal with Treovir Inc. for its G207 therapy. 3️⃣ Amarna Therapeutics partners with NorthX Biologics to accelerate gene therapy manufacturing. 4️⃣ VIVEbiotech receives strategic growth equity investment from Ampersand Capital Partners. 5️⃣ EXO Biologics earns GMP certification for its advanced exosome manufacturing facility in Europe. ✨ Leadership Moves: LOTTE BIOLOGICS appoints James Park as its new CEO. Swipe to learn more about these developments! -------------------- #CDMO #ContractManufacturing #TalentStrategy #Pharmaceuticals

5

1 Comment

🌟 Galapagos, a Flemish biotech company, has made a significant advancement by partnering with Adaptimmune to 𝐝𝐞𝐯𝐞𝐥𝐨𝐩 𝐧𝐞𝐱𝐭-𝐠𝐞𝐧𝐞𝐫𝐚𝐭𝐢𝐨𝐧 𝐓-𝐜𝐞𝐥𝐥 𝐭𝐡𝐞𝐫𝐚𝐩𝐲 𝐢𝐧 𝐚 𝐝𝐞𝐚𝐥 𝐯𝐚𝐥𝐮𝐞𝐝 𝐚𝐭 $𝟔𝟔𝟓 𝐦𝐢𝐥𝐥𝐢𝐨𝐧 𝐢𝐧 𝐛𝐢𝐨𝐛𝐮𝐜𝐤𝐬! This collaboration focuses on uza-cel, a MAGE-A4 TCR T-cell therapy initially designed for ovarian cancer. Galapagos plans to extend its application to head and neck cancer and other solid tumors. 🚀 Dr. Paul Stoffels, MD, Galapagos’ Chief Executive Officer and Chairman, stated: “𝑇ℎ𝑖𝑠 𝑐𝑜𝑙𝑙𝑎𝑏𝑜𝑟𝑎𝑡𝑖𝑜𝑛 𝑜𝑓𝑓𝑒𝑟𝑠 𝑡ℎ𝑒 𝑝𝑟𝑜𝑚𝑖𝑠𝑒 𝑓𝑜𝑟 𝑓𝑎𝑠𝑡𝑒𝑟 𝑎𝑐𝑐𝑒𝑠𝑠 𝑡𝑜 𝑎 𝑝𝑜𝑡𝑒𝑛𝑡𝑖𝑎𝑙𝑙𝑦 𝑡𝑟𝑎𝑛𝑠𝑓𝑜𝑟𝑚𝑎𝑡𝑖𝑣𝑒 𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡.” 🤝 The funding from this deal ensures the continuation of uza-cel's development and supports the launch of Adaptimmune's leading asset, afami-cel, for synovial sarcoma later this year. Adrian (Ad) Rawcliffe, Adaptimmune’s Chief Executive Officer, noted: “𝐶𝑜𝑚𝑏𝑖𝑛𝑖𝑛𝑔 𝑢𝑧𝑎-𝑐𝑒𝑙 𝑤𝑖𝑡ℎ 𝐺𝑎𝑙𝑎𝑝𝑎𝑔𝑜𝑠’ 𝑢𝑛𝑖𝑞𝑢𝑒 𝑑𝑒𝑐𝑒𝑛𝑡𝑟𝑎𝑙𝑖𝑧𝑒𝑑 𝑚𝑎𝑛𝑢𝑓𝑎𝑐𝑡𝑢𝑟𝑖𝑛𝑔 𝑝𝑙𝑎𝑡𝑓𝑜𝑟𝑚 𝑖𝑠 𝑎 𝑛𝑎𝑡𝑢𝑟𝑎𝑙 𝑠𝑦𝑛𝑒𝑟𝑔𝑦.” 📈 The news has positively impacted Adaptimmune's market performance, with a 21% surge in premarket trading. This collaboration underscores the 𝐢𝐦𝐩𝐨𝐫𝐭𝐚𝐧𝐜𝐞 𝐨𝐟 𝐢𝐧𝐭𝐞𝐫𝐧𝐚𝐭𝐢𝐨𝐧𝐚𝐥 𝐩𝐚𝐫𝐭𝐧𝐞𝐫𝐬𝐡𝐢𝐩𝐬 𝐢𝐧 𝐚𝐝𝐯𝐚𝐧𝐜𝐢𝐧𝐠 𝐢𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐯𝐞 𝐭𝐡𝐞𝐫𝐚𝐩𝐢𝐞𝐬, celebrated by entities like Flanders Investment & Trade (FIT). 📰: Fierce Biotech, flanders.bio  📸: Labiotech.eu 

146

⚗️ See you soon in Stockholm for #BIOEuropeFall, the major autumn event dedicated to healthcare biotechnologies and the pharmaceutical industry 💊 📆 From November 4 to 6, 2024 , Wallonia will be present with 50 Belgian companies from the life sciences sector. 🎯 Belgium is recognized as a hub for biotechnology and pharmaceutical innovation, with a strong #ecosystem that includes world-class #research institutions, cutting-edge #technology platforms and a collaborative environment that supports the growth 📈 of start-ups and established companies. 🤝 Join us at booth #96 to learn more about our region's assets and explore #partnership opportunities with our companies. 💡 As a reminder, Wallonia has set up an unprecedented technological innovation partnership in the field of #ATMPs (Advanced Therapy Medicinal Products). With over 20 years' experience in these new-generation biomedicines, the Walloon region intends to establish itself as a European leader in this field. 👉 More info: https://lnkd.in/dQebeUXe #innovation #lifesciences #health #wallonia #invest #biotech Wallonia Export & Investment Agency BioWin Wallonia in Sweden Amyl Therapeutics Artialis Celyad Oncology CER Groupe convEyXO DeuterOncology NV Estetra EuroscreenFast EXO Biologics EyeD Pharma Hyloris Pharmaceuticals IDDI - Regulatory Statistics & Clinical Data Science Experts InhaTarget Therapeutics Op2Lysis Réseau LiEU RLM Consulting Seqalis Spectralys Biotech Syngulon THERAtRAME Univercells SA White Raven

21

1 Comment

We are excited to announce the opening of our new biomanufacturing facility in Liège, Belgium, with Phase 1 set to be operational in Q1 2025. The facility is a major milestone for Samabriva, enabling industrial scale production of high value natural molecules for the manufacture of pharmaceuticals. The investment emphasises our strong commitment to delivering plant-based bioproduction at large scale. By providing customers with full control over the biomanufacturing process, we will deliver a cost effective and sustainable alternative to open field production. Read the full press release here: https://lnkd.in/gbmjuqdn Marina Guillet Bertrand Duquesne Pascal Lizin Florian Cardon #biomanufacturing #bioprocessing #bioproduction #Lifesciences #supplychain #biomolecules #pharmaceuticalindustry

106

4 Comments

🚨 atbtherapeutics Secures the Largest Series A in Wallonia: €54M!   A major milestone for Belgian biotech 🇧🇪: ATB Therapeutics, a pioneer in First-in-Class weaponized antibodies, has raised a record-breaking €54M Series A, co-led by EQT Life Sciences and MRL Ventures Fund LLC (@Merck & Co.), with the support of key investors, including Wallonie Entreprendre, V-Bio Ventures, and VIVES Partners.   ➡️ This funding will advance ATB’s revolutionary ATBioFarm platform, enabling the development of next-generation biologics that integrate targeting and cytotoxic functions in a single construct—transforming oncology and immunology treatments. The company also welcomes Mark Throsby as Executive Chair. With his extensive experience in antibody therapeutics, he will help ATB deliver on its mission to bring first-in-class therapies to patients.   This landmark achievement not only cements ATB’s position as a biotech trailblazer but also highlights Wallonia as a leader in global innovation. 🌍   Read the complet story in La Libre (links in the comments) 👇   Contact our team for your financial needs in Life Sciences (links in the comments) 👇   #lifesciences #funding

57

2 Comments

We are proud to share that our Life Sciences team has successfully supported ATB Therapeutics from Marche-en-Famenne, Belgium, in its €54 million Series A financing round! This exciting milestone, announced on November 18, 2024, underscores the potential of ATB’s groundbreaking platform for producing recombinant immunotoxins and its promising pipeline of anti-cancer drug candidates. This isn’t our first big biotech success this year! In July 2024, we also supported SciRhom GmbH in Germany with their €63 million Series A financing round. With these achievements, MHP is proud to represent two of the top five biotech startups ranked by Series A financing volume in continental Europe this year: 1️⃣ Adcendo – €98 million | Denmark 2️⃣ Calluna Pharma – €75 million | Norway 3️⃣ SciRhom GmbH – €63 million | Germany 4️⃣ AQEMIA – €60 million | France 5️⃣ ATB Therapeutics – €54 million | Belgium These successes are a testament to the expertise and dedication of our Life Sciences team in supporting biotech startups across Europe. Currently, we are proud to represent clients in 11 European countries, offering tailored support for their IP needs. Our mission goes beyond legal counsel—we strive to create value, attract investment, and help bring innovative therapies to market. Seeing our clients thrive is the ultimate reward! 🌟 If your biotech startup or spin-off is looking for expert IP support, don’t hesitate to reach out. We’re just a phone call away. 📞 #Biotech #Innovation #LifeSciences #SeriesA #Startups #MHPteam #IPExcellence

7

Founded in 2014 as a spin-off of the French Blood Bank (EFS), PDC*line Pharma is a Belgian-French clinical-stage biotech company that develops an innovative class of active immunotherapies for cancers, based on a GMP-grade allogeneic therapeutic cell line of Plasmacytoid Dendritic Cells (PDC*line). PDC*line is much more potent than conventional dendritic cell-based vaccines in priming and boosting antitumor antigen-specific cytotoxic T-cells, including the T-cells specific for neoantigens, and is synergistic with checkpoint inhibitors. The technology can potentially be applied to any type of cancer. Following a first-in-human phase I feasibility study in melanoma, PDC*line Pharma focuses on the development of PDC*lung01, a candidate for Non-Small-Cell Lung Cancer (NSCLC) currently in phase I/II trials, and PDC*neo with neoantigens in preclinical development. The company has a staff of 42, with an experienced management team. It has raised close to €61M in equity and non-dilutive funding. In March 2019, PDC*line Pharma granted an exclusive license to the LG Chem Life Sciences company in South Korea and an exclusive option in other Asian countries, for the development and commercialization of the PDC*lung01 cancer vaccine for lung cancer. The total deal is worth €108M, plus tiered royalties on net sales in Asia. Meet PDC*line Pharma SA @ #Sachs_BEF More Info @ https://lnkd.in/d7zEuKym #BigPharma #Dealmakers #PharmaIndustry #BiotechInEuropeForum #LifeSciences #Biotech #BioPharma #Partnering #Investment #Startups #Oncology #Neurology #Genomics #Immunotherapy #CNS #Autoimmune #Cardiovascular #BiotechIndustry #BioTechInvestment #Innovation #InvestmentForum #BiotechConference #EuropeanBiotech #SachsAutumnLifeSciencesWeek #SALSW

11

2 Comments

𝐒𝐏𝐈𝐌𝐀 𝐓𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜𝐬 𝐒𝐭𝐚𝐫𝐭𝐬 𝐖𝐢𝐭𝐡 𝐆𝐥𝐨𝐛𝐚𝐥 𝐋𝐢𝐜𝐞𝐧𝐜𝐞 𝐀𝐠𝐫𝐞𝐞𝐦𝐞𝐧𝐭 Montpellier-based start-up SPIMA Therapeutics has signed a global exclusive license agreement with the tech-transfer specialist SATT AxLR for its lead drug program, SPM001, a peptidic inhibitor of the Myddsome complex. SPIMA Therapeutics was co-founded by Prof. Christian Jorgensen, Prof. Jean Martinez, Mohamed Haitham Ayad, RPh, Ph.D. (CEO), Dr. Florence Apparailly, Dr. Muriel Amblard, and Swiss Landmark BioVentures AG (LBV). SPM001, SPIMA’s lead candidate, targets the Myddosome complex, a key untapped actor in the dysregulated innate inflammatory process. Demonstrating exceptional drug-like properties, SPM001 holds the potential to become a first-in-class treatment for severe immunological disorders and aggressive cancers driven by MyD88 mutation. SPIMA Therapeutics SATT AxLR Landmark BioVentures AG Zaki Sellam Muriel Amblard Florence Apparailly Jean Martinez Stéphanie Bonnin Mohamed Haitham Ayad #peptide #immunotherapies #cancr #oncology #stapledpeptide #inflammation #immunology #drugdiscovery #drugdevelopment

14

1 Comment

🔍 𝗨𝗻𝗹𝗼𝗰𝗸𝗶𝗻𝗴 𝘁𝗵𝗲 𝗣𝗼𝘁𝗲𝗻𝘁𝗶𝗮𝗹 𝗼𝗳 𝗛𝗲𝗮𝗹𝘁𝗵𝗧𝗲𝗰𝗵 𝗗𝗶𝗮𝗴𝗻𝗼𝘀𝘁𝗶𝗰𝘀 𝘄𝗶𝘁𝗵 𝗠𝗘𝗗𝗞𝗔𝗣 We’re excited to share insights from Frank Desiere - PhD MBA in our latest article on the 𝗗𝗶𝗮𝗴𝗻𝗼𝘀𝘁𝗶𝗰𝘀 𝗠𝗮𝗿𝗸𝗲𝘁! Discover why 𝗶𝗻𝘃𝗲𝘀𝘁𝗶𝗻𝗴 𝗶𝗻 𝗛𝗲𝗮𝗹𝘁𝗵𝗧𝗲𝗰𝗵 is not only a strategic financial decision but also a way to drive transformative healthcare solutions. From early disease detection to personalized treatments, diagnostics are shaping the future of medicine. 𝗪𝗵𝗮𝘁 𝘄𝗲 𝗰𝗼𝘃𝗲𝗿: - The market’s growth, projected to reach $109 billion by 2028. - Trends transforming diagnostics, like 𝗽𝗿𝗲𝗰𝗶𝘀𝗶𝗼𝗻 𝗺𝗲𝗱𝗶𝗰𝗶𝗻𝗲 and 𝗔𝗜 𝗶𝗻𝘁𝗲𝗴𝗿𝗮𝘁𝗶𝗼𝗻. - Cutting-edge advancements, such as 𝗹𝗶𝗾𝘂𝗶𝗱 𝗯𝗶𝗼𝗽𝘀𝗶𝗲𝘀 and 𝘄𝗲𝗮𝗿𝗮𝗯𝗹𝗲 𝗵𝗲𝗮𝗹𝘁𝗵 𝗺𝗼𝗻𝗶𝘁𝗼𝗿𝘀. - The opportunities and challenges awaiting investors in this dynamic sector. Explore the full article below and see how MEDKAP, through Dr. Frank Desiere's insights, is highlighting the revolutionary impact of diagnostics in healthcare!

9

3 Comments

Europe is losing its competitive edge when it comes advanced therapies. We need to understand how we can collaborate more on a European level to be more interesting as a partner. This knowledge could help us complement each other rather than compete against each other. Read this article featuring insights from Daniel Gibson (Cell and Gene Therapy Catapult), Kristina Levan (ATMP Sweden) and Sylvie Ponchaut (BioWin). https://lnkd.in/eMJrSjdY

1

“Most of the pharma companies back then were in silos, doing their own research, working only on their own assets, not connecting with academics and the wider startup biotech ecosystem.” Who would have thought that going against the current would have brought us this far? Check out the full interview from our CEO, Bertrand Ducrey, in The CEO Magazine Global, and follow us for updates on Debiopharm's pipeline evolution! 🌟 #ceo #interview #pharma #biotech

117

4 Comments

📄 [Press Release] – MaaT Pharma is proud to announce the successful completion of its Global Offering of 19.2 Million Euros ▪ Support from historical investors Bpifrance, Seventure Partners, Biocodex, and from the management of the Company ▪ 70% of new retail investors previously non-shareholders joined us, showcasing a strong influx of new support, with a total investment of €0.9 million ▪ Financing will enable the Company to extend its cash runway through early Q1 2025 ▪ The net proceeds from the Primary Offering will be used to fund the company’s R&D activities, covering completion of the Phase 3 trial for MaaT013 in Europe, including top-line results/primary endpoint in mid Q4 2024, continuing the pipeline development, including the initiation of Phase 3 trial activities for MaaT013 in the US and the broadening of the Phase 2b trial with MaaT033 across Europe and for working capital and other general corporate purposes, including repayment of current debts. 👉 Read the press release here: https://lnkd.in/efFj8Ube

97

2 Comments